Paper19084016
Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
Liu CJ and 18 others. Gastroenterology, 2009. Cited by 170 papers, by iCite.
Cite this record
ConductScience Library. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Papers, record 19084016. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19084016
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics23
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antiviral Agents | Major topic |
| Hepatitis B | Major topic |
| Hepatitis C | Major topic |
| Interferon-alpha | Major topic |
| Polyethylene Glycols | Major topic |
| Ribavirin | Major topic |
| Adult | |
| Antibodies, Viral | |
| DNA, Viral | |
| Dose-Response Relationship, Drug | |
| Drug Therapy, Combination | |
| Female | |
| Hepacivirus | |
| Hepatitis B virus | |
| Humans | |
| Interferon alpha-2 | |
| Male | |
| Middle Aged | |
| Recombinant Proteins | |
| Taiwan | |
| Treatment Outcome | |
| Viral Interference | |
| Viral Load |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00361179 | Long Term Effects of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/B Co-Infection and Chronic Hepatitis C | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT02060058 | Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy | Background | ClinicalTrials.gov |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 19105960 | Treatment of HBV/HCV coinfection: releasing the enemy within. | https://conductscience.org/library/papers/19105960 |
Source PubMed
Cited by70
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 170 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41508339 | Treatment strategies for patients with hepatitis B virus infection coexisting with hepatitis C virus or metabolic dysfunction-associated steatotic liver disease. | Clin Mol Hepatol | 2026 | https://conductscience.org/library/papers/41508339 | PubMed |
| 40445953 | Risk of HBV reactivation in HBV/HCV-co-infected HCV-treated patients: A single-center study. | PLoS One | 2025 | https://conductscience.org/library/papers/40445953 | PubMed |
| 39971544 | [Research progress on hepatitis B combined with C and its treatment]. | Zhonghua Gan Zang Bing Za Zhi | 2024 | https://conductscience.org/library/papers/39971544 | PubMed |
| 39743539 | HBV DNA integration and somatic mutations in HCC patients with HBV-HCV dual infection reveals profiles intermediate between HBV- and HCV-related HCC. | J Biomed Sci | 2025 | https://conductscience.org/library/papers/39743539 | PubMed |
| 36004906 | A Biotechnological Approach for the Production of Pharmaceutically Active Human Interferon-α from Raphanus sativus L. Plants. | Bioengineering (Basel) | 2022 | https://conductscience.org/library/papers/36004906 | PubMed |
| 34864948 | Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment. | Clin Infect Dis | 2022 | https://conductscience.org/library/papers/34864948 | PubMed |
| 34365587 | Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). | Hepatol Int | 2021 | https://conductscience.org/library/papers/34365587 | PubMed |
| 33765123 | The endoplasmic reticulum unfolded protein response - homeostasis, cell death and evolution in virus infections. | FEMS Microbiol Rev | 2021 | https://conductscience.org/library/papers/33765123 | PubMed |
| 32875000 | Viral Interference Between Dengue Virus and Hepatitis C Virus Infections. | Open Forum Infect Dis | 2020 | https://conductscience.org/library/papers/32875000 | PubMed |
| 32664198 | Hepatitis C Virus and Hepatitis B Virus Co-Infection. | Viruses | 2020 | https://conductscience.org/library/papers/32664198 | PubMed |
| 31565002 | Impact of chronic schistosomiasis and HBV/HCV co-infection on the liver: current perspectives. | Hepat Med | 2019 | https://conductscience.org/library/papers/31565002 | PubMed |
| 31540223 | Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV). | Viruses | 2019 | https://conductscience.org/library/papers/31540223 | PubMed |
| 31357767 | [Research progress of hepatitis B and C virus co-infection]. | Zhonghua Gan Zang Bing Za Zhi | 2019 | https://conductscience.org/library/papers/31357767 | PubMed |
| 31276038 | Economic evaluation of direct-acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore. | JGH Open | 2019 | https://conductscience.org/library/papers/31276038 | PubMed |
| 30992821 | Viral hepatitis B coinfection with human immunodeficiency virus, hepatitis D virus, or hepatitis C virus. | Clin Liver Dis (Hoboken) | 2013 | https://conductscience.org/library/papers/30992821 | PubMed |
| 30557991 | A scoring system to predict HBsAg seroclearance in hepatitis B and C coinfected patients treated with interferon and ribavirin in an Asian cohort. | Medicine (Baltimore) | 2018 | https://conductscience.org/library/papers/30557991 | PubMed |
| 30543053 | Engineering Chlamydomonas reinhardtii for Expression of Functionally Active Human Interferon-α. | Mol Biotechnol | 2019 | https://conductscience.org/library/papers/30543053 | PubMed |
| 30271742 | HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation. | J Clin Transl Hepatol | 2018 | https://conductscience.org/library/papers/30271742 | PubMed |
| 30092624 | 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C. | Clin Mol Hepatol | 2018 | https://conductscience.org/library/papers/30092624 | PubMed |
| 30065564 | Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis. | World J Gastroenterol | 2018 | https://conductscience.org/library/papers/30065564 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| IFNA2 | 3440 | PubTator's text mining | https://conductscience.org/library/genes/3440 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19084016
GET https://conductscience.org/api/papers/v1/19084016/cited_by?page=2